Skip to main content
Premium Trial:

Request an Annual Quote

Former Gemini CEO Paul Kelly Takes Helm at Orchid

NEW YORK, May 28 - Orchid Biosciences has appointed Paul Kelly as its new CEO, filling a position left vacant when Dale Pfost left in December 2002, the company announced today.

 

Kelly, 43, is an Australian-born endocrinologist and the former CEO of Gemini Genomics, which he co-founded in 1995. Gemini, a clinical genomics company that collected genetic, clinical, and environmental data from different human populations and analyzed this data to look for drug targets, merged with Sequenom in 2001.

 

Since leaving Gemini, Kelly founded Nanovis, a materials science company, and AgaMatrix, a medical devices  company. He most recently held the CEO post at data analysis company OmniViz.

 

"We believe that Paul has the right mix of vision and hands-on expertise in the commercialization of clinical genetics, genoprofiling and research services for the biomedical and biotechnology sectors to take Orchid to its next stage of growth," said George Poste, chairman of Orchid, in a statement.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.